Intravenous Immunoglobulin for Relapsing-Remitting Multiple Sclerosis Treatment: A Case Report and Literature ReviewKunfang Yang, Rongrong Yin, Hongyi Cheng, Yuanfeng Zhang, Simei Wang, Chunmei Wang, Yanfen Lu, Jiaming Xi, Qin Lu, Jianjun Huang and Yucai Chen*
Department of Neurology, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai 200062, China
- *Corresponding Author:
- Yucai C
Department of Neurology
Shanghai Children’s Hospital
Shanghai Jiao Tong University
Shanghai 200062, China
E-mail: [email protected]
Received date: February 06, 2017; Accepted date: February 21, 2017; Published date: February 28, 2017
Citation: Yang K, Yin R, Cheng H, Zhang Y, Wang S, et al. (2017) Intravenous Immunoglobulin for Relapsing-Remitting Multiple Sclerosis Treatment: A Case Report and Literature Review. J Mult Scler 4:196. doi:10.4172/2376-0389.1000196
Copyright: ©2017 Yang K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background/aim: Multiple sclerosis (MS) is a chronic and debilitating inflammatory autoimmune disease of the central nervous system (CNS) that affects the myelinated axons in the CNS. Incomplete remissions occur more commonly with increasing duration of disease. Intravenous immunoglobulin (IVIg) has various functions as an immune modulator via macrophage activation. Clinical trials of immunoglobulin demonstrated remarkable clinical effects in several types of MS, especially in relapsing-remitting type. It is an approved method for the treatment of relapsing-remitting MS that can be used as a supportive therapy. Our study involves the case of a ten year old female patient with relapsing-remitting MS. This study was undertaken to examine the effects of IVIg used almost every 6 months in a patient with relapsing-remitting MS. Results: This case study demonstrated that treatments of IVIg used almost every 6 months in a patient with relapsing-remitting MS have potent therapeutic actions with early beneficial responses. Conclusion: IVIg used almost every 6 months shows a potential positive therapeutic treatment for relapsingremitting MS and more large-scale clinical studies are required.